Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

es each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at www.pharmacyclics.com.

The following safety information is described in the package insert for the use of IMBRUVICA in patients with MANTLE CELL LYMPHOMA who have received at least one prior therapy. This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage - 5% of patients with MCL had ≥ Grade 3 bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria). Bleeding events including bruising of any grade occurred in 48% of patients with MCL treated with 560 mg daily. The mechanism for the bleeding events is not well understood. Consider the benefit-risk of IMBRUVICA in patients requiring antiplatelet or anticoagulant therapies and the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections - Fatal and non-fatal infections have occurred. At least 25% of patients with MCL had infections ≥ Grade 3, according to NCI Common Terminology Criteria for Adverse Events (CTCAE). Monitor patients for fever and infections and evaluate promptly.

Myelosuppression - Treatment-emergent Grade 3 or 4 cytopenias were reported in 41% of patients. These included neutropenia (29%), thrombocytopenia (17%) and anemia (9%). Monitor complete blood counts monthly.

Renal Toxicity - Fatal and serious cases of renal failure have occurred. Treatment-emergent increases in creatinine levels up to 1.5 times the uppe
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... IRVING, Texas , Sept. 17, 2014 /PRNewswire/ ... Physician Direct Accountable Care Organization (Physician Direct ACO) ... help their physicians in providing better care while ... Physician Direct Accountable Care ... Physician Network Services (OPNS). The OPNS mission is ...
(Date:9/17/2014)... , Sept. 17, 2014   MedeAnalytics ... solution that brings complete visibility to a provider,s ... an ever-evolving reimbursement landscape. Powered by the industry,s ... to the critical point between patient access and ... The solution will improve revenue capture, minimize audit ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2
... , JERUSALEM , Jan. ... company, announced today that it has granted Novartis an option to ... Permeability Enhancer (TPE) technology for use with certain related small molecule ... a separate but related agreement, the MPM Bio IV NVS Strategic ...
... , FRANKLIN LAKES, N.J. , Jan. 19 ... scheduled to present at the following investor conferences: , Brian Griffin ... Global Healthcare Services Conference on Monday, January 25, 2010 at ... New York ; , David B. Snow Jr. , Medco chairman ...
Cached Medicine Technology:Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3Medco to Present at Upcoming Investor Conferences 2
(Date:9/17/2014)... September 17, 2014 Functional Fitness Solution ... and Dr. Cody Sipe that is helping middle-aged adults minimize ... longevity has caught the attention of Shane Michaels, prompting an ... their 50s, 60s, or even 70s what would be the ... a day-to-day basis, they would probably answer that the just ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In its latest ... programs and believes that having family close by during a ... or not the process is successful, is highlighting a member ... difference in the lives of addicts across the country and ... pet therapy can reduce the blood pressure, heart rate, and ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 The Oliver Law Group P.C. ... caused by Non-Sterile Other-Sonic Ultrasound Transmission Gel to ... options for legal recourse. Other-Sonic ultrasound gel was recalled ... March 2012, after the product was linked to a ... Hospital in Royal Oak, Michigan . While victims of ...
(Date:9/17/2014)... Rockville Centre, NY (PRWEB) September 17, 2014 ... the court acknowledges that “bi-weekly telephonic discovery conferences would ... scheduled seven such conferences through mid-December. “At the end ... counsel will assess the need for additional conferences. ... the court recognizes that there is still much to ...
Breaking Medicine News(10 mins):Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2
... constipation are more likely to get diagnosed with the progressive ... have// some effect on the function of the gut long ... led the research, said: "It could help us more effectively ... high risk of developing the disease in the future." The ...
... type of childhood brain cancer has a unique molecule ... fight it.// Armed with targeted molecular treatments, doctors may ... side effects of prolonged and powerful radiation and chemotherapy ... a collaborative effort looking at a type of childhood ...
... A new invenvtion in the medical history. A team of ... a 68-year old woman using a remote controlled robot. This ... medical history. The operation took place at the European Institute ... it is a phenomenal step and we cannot even begin ...
... the Institute of Health Sciences in Oxford found that women ... to have a stillbirth, or to develop pre-eclampsia.// Taking low-dose ... researchers. ,The researchers reviewed more than 23 previous ... of anti-platelet drugs, of which low-dose aspirin is the most ...
... errors in the alpha gene are the cause of premature ... affects about 2% of the total population.// ,The University ... development of a genetic test, which would allow women with ... are at risk. They analysed DNA from women who had ...
... and marketing rights of the anti-anthrax vaccine developed by the ... is expected that the vaccine would be in the market ... to JNU for the exclusive rights. In addition, it will ... is yet to make any projections on the business the ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: